CN201316330Y - Combined tissue-engineered coelomic duct substitute - Google Patents
Combined tissue-engineered coelomic duct substitute Download PDFInfo
- Publication number
- CN201316330Y CN201316330Y CNU2008202018743U CN200820201874U CN201316330Y CN 201316330 Y CN201316330 Y CN 201316330Y CN U2008202018743 U CNU2008202018743 U CN U2008202018743U CN 200820201874 U CN200820201874 U CN 200820201874U CN 201316330 Y CN201316330 Y CN 201316330Y
- Authority
- CN
- China
- Prior art keywords
- human body
- succedaneum
- tissue engineering
- body lumen
- combined human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
A combined tissue-engineered coelomic duct substitute adopts a coated elastic supporting tube with connectors, an absorbable coating is attached on the outer wall of the supporting tube, and seed cells are planted on the absorbable coating. The connectors can effectively reduce the affection of esophageal peristalsis on the implanted elastic supporting tube, and with the good suppleness and strong supporting force of the elastic supporting tube, the coelomic duct substitute of the utility model can prevent anastomotic fistula, early decannulation and neo-esophagus stenosis. In addition, the absorbable coating attached on the elastic supporting tube, on which the seed cells are planted, can induce or promote the growth and covering of the mucous membrane of the neo-esophagus. After the full covering of the mucous membrane of the neo-esophagus and the stabilization of the scar tissues of the neo-esophagus, the implanted substitute is taken out or removed under the direct view of a gastrointestinal endoscope.
Description
Technical field
The artificial human body intracavity duct that this utility model uses when relating to a kind of artificial human body intracavity duct, particularly esophageal reconstruction, tracheal reconstruction.
Background technology
In the time need excising esophagus because of tumor, usually adopt to promote stomach or intestinal tube and rebuild gastral way with the esophagus proximal anastomosis and solve in the prior art, this method damage and is non-physiology passage of food greatly, has much to be difficult to the complication that overcomes; And the trachea pathological changes does not also have ideal tracheal reconstruction succedaneum need excise the above trachea of 3cm the time at present.
With the esophagus is example, and the esophageal carcinoma is Chinese commonly encountered diseases, occupies the second in the common malignancy sickness rate, and sickness rate is 21,/10 ten thousand, promptly increase patient year newly more than 27.3 ten thousand, and sickness rate also has the trend that rises at present, very harmful.The esophageal injury that the esophageal injury, particularly traffic accident that causes because of a variety of causes simultaneously causes, also in rising trend.How effectively to implement the esophageal reconstruction art, be to reduce mortality rate and improve patient's key of quality of life.
The focus of the esophageal carcinoma has the characteristics of multicenter jumping characteristic usually, and up to now, the most effective Therapeutic Method of the esophageal carcinoma is still and adopts surgical resection pathological changes esophagus, and uses substitute simultaneously the esophagus passage is carried out esophageal reconstruction, to recover the esophagus passage.
Because the supply vessels of esophagus is tiny blood vessel network, tiny blood vessel is difficult to coincide during the esophagus transplanting, and the blood supply of the esophagus of transplanting is difficult to rebuild, thereby esophagus is difficult to carry out organ transplantation as organs such as heart, liver, kidney.
At present, mainly adopt patient's self other tissue or organ to come restoration and reconstruction esophagus passage clinically, as with stomach or intestinal is carried to the thoracic cavity from the abdominal cavity or the normal esophageal end-to-end anastomosis of cervical region and reservation comes restoration and reconstruction esophagus passage, this traditional operation method has following shortcoming: operation wound is big, the time is long, the anatomical organ displacement causes influenced and digestive functional disturbance of cardio-pulmonary function etc.
After the esophageal carcinoma esophagus excision, the most frequently used operation method is " putting forward the stomach method ", is about to stomach and mentions the normal esophageal broken ends of fractured bone of thoracic cavity and reservation from the abdominal cavity and carry out the esophagus end-to-end anastomosis, rebuilds the esophagus passage with this kind method.Because stomach is mentioned thoracic cavity (being called for short the breast stomach), stomach can be oppressed cardiopulmonary, has a strong impact on cardio-pulmonary function.In order to reduce of the influence of breast stomach to cardio-pulmonary function, carry out stomach usually simultaneously and dwindle art, but dwindling art, stomach can cause side effect such as digestive functional disturbance again, influence patient's quality of life.
Another kind of more common operation method is " intestinal is for the esophagus method ", after being the esophagus excision, the intestinal of forming with band blood vessels such as jejunum or colons replaces the esophagus of excision, to replace the esophagus of excision be method preferably to the intestinal of forming with the band blood vessel in theory, because intestinal itself has digestive function and wriggling function, but it is actually rare that clinical practice is used, and its main cause is that operation wound is big, the time is long, clinical effectiveness is unstable.Carry out this operation, earlier will be from abdominal part free and excise jejunum or the colon that suitable band blood vessel is formed, the broken ends of fractured bone of transferring to thoracic cavity and esophagus then carries out end to end anastomosis, the blood vessel of jejunum or colon will be formed with near supply vessels identical simultaneously.Because the wriggling of the wriggling of intestinal and esophagus is proportioning not, and esophagus-intestinal anastomotic stoma fistula often takes place, the vascular anastomosis place is also stopped up easily in addition, causes the jejunum or the colon necrosis of transplanting, and finally causes operative failure.For the jejunum that improves transplanting or the survival rate of colon, also adopted a kind of improved modus operandi, promptly the blood vessel of jejunum or colon is not formed cut-out, still keep former blood supply passage, and only move the jejunum or the colon that cut off to thoracic cavity, carry out end to end anastomosis with the esophagus broken ends of fractured bone that keeps and rebuild the esophagus passage, but because blood vessel is formed the restriction of length and blood supply ability, this method is used also few at clinical practice.Also have method such as transfer of skin flap to rebuild the esophagus passage in addition, because clinical effectiveness is undesirable or side effect is many, practical application seldom.What be worth paying special attention to is, average 5 years survival rates of esophageal carcinoma postoperative are less than 20%, and 80% advanced esophageal carcinoma patient postoperative is dead in 2 years, and 5 years survival rates of postoperative of this and other tumor relatively have distance greatly.Though many-sided reason is arranged, thereby lacking effective succedaneum, esophagus excision back cause operation wound big, dissect dystopy, patient's postoperative nutrition intake deficiency, poor life quality is an important reasons.Just because of this, the market prospect of artificial esophagus and social meaning, can quote the yellow tame professor of a team of four horses of the Chinese thoracic surgery older generation and summarize: " though what years, if artificial esophagus research achieving success, exactly the invention that promotes the well-being of mankind! "
1913, U.S. Cardiac surgeon Franz J.A.Torek became the doctor of first clinical use artificial esophagus in the world, and Torek is the artificial esophagus that women's patient with esophageal carcinoma of 67 years old has used external arrangement.At first he is to patient throat fistulation, carry out the stomach fistulation simultaneously, silica gel tube by external placement links together throat fistulization oral stomach function regulating fistulization oral then, patient's per os crunching food, food is swallowed after the throat fistulization oral flows into silica gel tube, flow into stomach through the stomach fistulization oral again, the patient has successfully survived 13 years, dies from pulmonary infection at last.The result that this is clinical has not only inspired the research enthusiasm of artificial esophagus greatly, and has obtained an important conclusions: the esophagus most important function is the channel function of food, as long as food can enter stomach through passage, the patient just can long term survival.
Because external artificial esophagus patient is difficult to accept, people just look on the bright side of things always and send out the artificial esophagus that body is implanted into.
From nineteen fifty-three Berman etc. take the lead in adopting special polyethylene tube substitute esophagus damaged since, silicone rubber subsequently, terylene (Dacron), politef (Teflon), carbon fiber, various metal materials etc. all successively are used to study the manufacture of intraocular esophagus, but all fail to attain the results expected.Purushotham in 1991 etc. study using absorbable acellular timbering material manufacture of intraocular esophagus, its method is to adopt Biodegradable material and non-degradable macromolecular material to constitute complex, by inducing the regeneration of receptor esophageal tissue, carry out esophageal reconstruction, though in zoopery, obtained satisfied result, but equally also there is more defective, only be suitable for the damaged short scope of esophagus as this type of experimental technique, still there are bigger gap in the esophageal tissue of regeneration induction and self esophageal tissue on 26S Proteasome Structure and Function.Application organizes engineerings such as Yamamoto were carried out the research of people's esophagus in 2000, this is to use the application that autologous tissue's cells in vitro is cultivated " organizational project " notion of the tissue grafts with physiological function, and the effect of engineered esophagus in concrete clinical practice is on the knees of the gods.Application Ultimum Ti rings such as Japanese Watanabe M produced the artificial esophagus that can wriggle in 2005, and did the animal experiment with sheep, and the result remains to be observed.
The artificial esophagus research of China is also very active, in early days, Shanghai uses silica gel to cover nylon tube (1972), Beijing trial pericardium covering " Teflon " (Teflon) is managed (1986) and carried out the research of artificial esophagus, but the same with external similar research, fails to attain the results expected.Over past ten years, China has formed the scientific research and development situation of standing like the legs of a tripod of Biodegradable artificial esophagus, Biotype artificial esophagus and memory alloy artificial esophagus.
The Biodegradable artificial esophagus is based on Shanghai, and Core Team has Qin Xiong, the Xu Zhifei of Long March hospital of The 2nd Army Medical College cardiothoracic surgery and Sun Kang, the height of Shanghai Communications University's composite institute to face south etc.Made up polyurethane-collagen protein chitosan combined artificial esophagus, and the patent of having applied for " degradable combined artificial esophagus and preparation method thereof " by Sun Kang etc., application number 200310107965.2, from the data of its paper of publishing, technical problems such as fistula of operative incision, newborn esophagostenosis are still waiting to solve.In addition, the Bao Chunrong of Changhai Hospital Affiliated to Army Surgeon Univ. No.2, Shanghai's cardiothoracic surgery etc. is also in the experimentation of carrying out artificial bio-membrane's biodegradable stent polylactic acid-polyglycolic acid plantation human body esophageal epithelial cell.The Xu Guofeng professor of Guangzhou Ji'nan University discloses " a kind of artificial esophagus with mechanics compliance " made with biodegradation material in utility model patent 03222722.1, but fails to retrieve zooperal data.
Zhang Lanjun, army eisenocher have been applied for the patent of " artificial esophagus " in 2003, application number: 03113536.6, a kind of Biotype artificial esophagus is disclosed, be that tissues such as aorta, cartilage, peritoneum with pig go antigenize to handle to make after (deactivation) to form, data from the paper published, adopt different biological material artificial esophaguses with different methods of anastomosis, the incidence rate of fistula of operative incision can drop to 6.67% (2/30) by 40% (6/15), but the narrow problem of newborn esophagus has to be solved.
Fang Lide in Chinese patent 00263467.8, disclose on a kind of wire netting and the wire netting body made with macromolecular compound, on the artificial esophagus that increases of lower nozzle place diameter, its similar is in esophageal stents appear, difference is that the film of its body has three layers, is silica gel, real silk and terylene successively.
1992, begin to use clinically based on the self-inflated esophagus bare bracket of niti-shaped memorial alloy technology, be used for the dilation therapy of late esophagus cancer patient esophagostenosis, obtain tangible curative effect, and popularize clinically beginning in 1994.Along with being extensive use of of memorial alloy esophagus bare bracket, its shortcoming is also obvious gradually, and cancerous tissue can pass the mesh of bare bracket, and entad growth causes restenosis.So nineteen ninety-five begins to have released memorial alloy band film esophageal stents appear, so far, memorial alloy band film esophageal stents appear clinically successful Application 13 years, settled the late esophagus cancer patient of esophageal stents appear, before because of cancerous cell diffusion death, still can normally take food.Band film esophageal stents appear not only is used for the dilation therapy of late esophagus cancer patient esophagostenosis, and is used for the treatment of esophageal fistula.It is damaged that large-scale esophageal fistula is equivalent to partial esophagus, adopt the treatment of memorial alloy band film esophageal stents appear that good curative effect is arranged, therefore, the inventor has produced the idea of exploitation artificial esophagus on the technical foundation of memorial alloy band film esophageal stents appear in June, 1999, based on this design of this technical foundation, might solve the technical barrier of two cores in the artificial esophagus research: the problem of fistula of operative incision and newborn esophagostenosis.
The inventor begins to develop artificial esophagus in June, 1999, on preliminary zooperal basis, January calendar year 2001, (patent name: the novel artificial intracavity duct) in Chinese patent 01107515.5, a kind of artificial intracavity duct with connecting ring is disclosed, adopted on the band film memorial alloy wire mesh tube body design that subtracts a connecting ring has been installed, be used for esophageal reconstruction or tracheal reconstruction.In the Chinese patent 200610122449.0 of my application, carried out perfect subsequently.At present, carried out the zoopery in 9 years, the survival period of the longest zoopery pig surpasses 5 years, and relevant at present product has obtained the clinical trial permission of Chinese Government, is in clinical experimental stage.In the zoopery and clinical experiment carried out; obtained The First Affiliated Hospital of Kunming Medical School Liang Jianhui professor; the Fu Jianhua of Zhongshan Univ. Cancer Cure Center professor, Li Yanfang associate professor; people's such as the anticipatory remark of BJ Univ Hospital, Shenzhen is taught admittedly, Xie Yuancai doctor support energetically; the data of the paper of publishing are seen: no fistula of operative incision, artificial esophagus can effectively prevent newborn esophagostenosis.
In sum: through the unremitting effort of last 100 years, the progress at full speed of bio-medical material and biotechnology over particularly past 50 years, the research and development of artificial esophagus were to thick long-pending moment of breaking out, the eve that core technology breaks through.By to over 100 years the summary of technical foundation, can obtain following conclusion:
(1) the esophagus most important function is the channel function of food, as long as food can enter stomach through passage, the patient just can long term survival.
(2) in the zoopery of carrying out with hybrid dog, cross-bred pig, outside the artificial esophagus of implanting, found the passage of a parcel artificial esophagus, i.e. so-called " newborn esophagus ".
(3) newborn esophagus can epithelization.
(4) newborn esophagus can be narrow.
But big difference is arranged on the histological structure of the formation reason of newborn esophagus and newborn esophagus.The inventor is in the zooperal research in 9 years, by 30 days to 4 years zooperal specimen having been carried out think that newborn esophagus is the cicatrix pipeline that the esophagus mucosa covers behind a large amount of histologic analysis.Thereby the inventor thinks that the artificial esophagus of implanting will succeed, and most crucial has two.The first, fistula of operative incision can not appear in two identical ends of artificial esophagus, and it is 0% to be primary goal that artificial esophagus is implanted back fistula of operative incision incidence rate, and this being even more important in early days after artificial esophagus is implanted can not avoid fistula of operative incision just might face operative failure.The second, the time that artificial esophagus is detained in vivo will be longer than the contractility that 6 months ability is effectively alleviated the scar tissue of newborn esophagus at least, prevents the narrow of newborn esophagus.More satisfactory supporting time is 18 months to 30 months.After 18 months to 30 months newborn esophagus can not only epithelization and also scar tissue can stablize, even if at this moment remove the support and the protection of artificial esophagus, newborn esophagus still can be narrow and infects.Therefore, connecting ring is for the body of artificial esophagus, and is extremely important.Can connecting ring effectively reduce the influence of esophageal peristalsis to the implantation body, thereby prevent fistula of operative incision and take off pipe in early days, directly determined the success or failure of operation.
In sum: after also lacking a kind of implantation in the prior art fistula of operative incision does not take place, can induce and promote the growth of the mucosa of newborn esophagus to cover, be highly resistant to the contractility of newborn esophagus scar tissue, prevent the narrow of newborn esophagus, and the mucosa of newborn esophagus cover fully and newborn esophagus scar tissue stable after, the artificial esophagus that can take out or remove by the mode of no wound or Wicresoft's wound.Therefore, need improve existing artificial esophagus.
Summary of the invention
The purpose of this utility model is to provide a kind of artificial esophagus, the succedaneum of human body esophageal reconstruction particularly, fistula of operative incision does not take place after the implantation, can induce and promote the growth of the mucosa of newborn esophagus to cover, be highly resistant to the contractility of newborn esophagus scar tissue, prevent the narrow of newborn esophagus, and the mucosa of newborn esophagus cover fully and newborn esophagus scar tissue stable after, can take out or remove by the mode of no wound or Wicresoft's wound.
The purpose of this utility model is achieved in that
Tissue engineering combined human body lumen succedaneum, by stay pipe (1), connector (2) but absorber coatings (3) and seed cell (4) are formed; Described stay pipe (1) is made of flexible supporting frames (11) and flexible material film (12), and flexible material film (12) is attached on the flexible supporting frames (11); But on the outer wall of absorber coatings (3) attached to stay pipe (1); Seed cell (4) but be planted on the absorber coatings (3); Connector (2) is fixed on the position of close end of stay pipe (1).
Described flexible supporting frames (11) is the network structure body that medical metal material silk or fibrage become; Or the network structure body of the helical spring of medical metal material spun gold coiled composition; Or the crooked resilient medical metal material thin-walled network structure body of energy through forming after the digital control processing; Or through the crooked resilient medical metal material thin-walled network structure body of energy behind the laser engraving.
Further, described medical metal material is selected from: niti-shaped memorial alloy (Nitinol alloy), beta-titanium alloy, medical stainless steel, medical zircaloy, medical zirconium-niobium alloy.
Described connector (2) is the circulus with the medical flexible material manufacture.
Further, described connector (2) is with medical flexible material silk or fiber, by the circulus of braiding or knitting manufacturing, the medical flexible material that connector (2) adopts is selected from: terylene (dacron fibre), polyethylene, polypropylene, polyurethane, politef.
But described absorber coatings (3) is the absorbable biological material coating that can use in human body, be selected from: polylactic acid, polyglycolic acid, poly(hydrobutyl ester), poly-anhydride, polycaprolactone, poly-phosphazo, polyphosphazene, polyamino acid, false polyamino acid, poe, polyester urethane, PTMC, Polyethylene Glycol, poly-P-Dioxane ketone, chitosan, collagen, gelatin, hyaluronic acid, chitin, alginate, calcium alginate gel, acellular matrix, bio-vitric, and copolymer or mixture.
But described absorber coatings (3) includes somatomedin, is selected from: platelet class somatomedin (platelet source somatomedin, PDGF; Osteosarcoma source somatomedin ODGF), epidermal growth factor subclass (epidermal growth factor, EGF, transforming growth factor, TGF α and TGF β), fibroblast growth factor (FGF, α FGF, β FGF), insulin like growth factor (IGF-I, IGF-II), nerve growth factor (NGF), interleukin class somatomedin (IL-1, IL-2, IL-3 etc.), erythropoietin (EPO), colony stimulating factor (CSF), and composition thereof.
Described seed cell (4) is selected from: from stem cell between stem cell, allogeneic bone marrow between body esophagus mucosal epithelium cell, autologous bone marrow, and composition thereof.
But described absorber coatings (3) includes somatomedin and collagen.
Further, but described absorber coatings (3) includes fibroblast growth factor (FGF) and collagen.
But described absorber coatings (3) includes somatomedin, collagen and chitosan.
Further, but described absorber coatings (3) includes fibroblast growth factor (FGF), collagen and chitosan.
But described absorber coatings (3) includes somatomedin and acellular matrix.
Further, but described absorber coatings (3) includes fibroblast growth factor (FGF) and acellular matrix.
But described absorber coatings (3) includes somatomedin, collagen and acellular matrix.
Further, but described absorber coatings (3) includes fibroblast growth factor (FGF), collagen and acellular matrix.
But described absorber coatings (3) includes somatomedin and polylactic acid.
Further, but described absorber coatings (3) includes fibroblast growth factor (FGF) and polylactic acid.
But described absorber coatings (3) includes somatomedin and polylactic acid-polycaprolactone copolymer.
Further, but described absorber coatings (3) includes fibroblast growth factor (FGF) and polylactic acid-polycaprolactone copolymer.
But described absorber coatings (3) includes somatomedin and bio-vitric.
Further, but described absorber coatings (3) includes fibroblast growth factor (FGF) and bio-vitric.
But described absorber coatings (3) includes somatomedin, collagen and bio-vitric.
Further, but described absorber coatings (3) includes fibroblast growth factor (FGF), collagen and bio-vitric.
Described stay pipe (1) can have different geometries, has: cylinder tube shape, the single bell-mouthed cylinder tube shape of band, the two single bell-mouthed cylinder tube shapes of band.
Described flexible material film (12) is to be selected from: medical silica-gel, polyurethane, politef at the thin film of the medium-term and long-term medical flexible material manufacture of implanting of human body.
Described connector (2) passes through operation suture thread (7) sutured on stay pipe (1).
The exhausting line (5) that takes out body has been installed in the upper end of described stay pipe (1).
The lower end of described stay pipe (1) is provided with anti-recirculation device (6).
Further, described anti-recirculation device (6) is petal-shaped structure, has: 2 lobe formula structures, 3 lobe formula structures, 4 lobe formula structures, 5 lobe formula structures, 6 lobe formula structures.
Described anti-recirculation device (6) is an oversleeve type check valve-type structure.
Described connector (2) is fixed on the stay pipe, apart from the about 5mm in the end of stay pipe～50mm place.
But the thickness of described absorber coatings (3) is between 1 μ m to 10mm, and preferred values is between 10 μ m to 3000 μ m.
Because this utility model has adopted the tectorial elastic stay pipe of band connector, but is attached with absorber coatings on the outer wall of its stay pipe, is implanted with seed cell but plant on the absorber coatings.Connector can effectively reduce the influence of esophageal peristalsis to the body of the elastic supporting pipe implanted, adds compliance that elastic supporting pipe is good and stronger support force, and the artificial esophagus of this utility model can prevent fistula of operative incision, take off pipe and newborn esophagostenosis in early days.In addition, but attached to the absorber coatings of having planted seed cell on the elastic supporting pipe, can induce or promote growth, the covering of newborn esophagus mucosa.Mucosa at newborn esophagus covers and the stable back of newborn esophagus scar tissue (about 6 months to 30 months) fully, under the direct-view of digestive endoscopy, removes stitching thread.Can be conveniently the elastic supporting pipe of the overlay film of the band connector implanted be taken out or removed.If when adopting degradation time to surpass 180 days the particular procedure suturing with thread management esophagus broken ends of fractured bone and connector (or address is connecting ring, or subtract a connecting ring), then need not remove stitching thread, after the operation suture thread degraded, stay pipe slippage is automatically fallen in the stomach, takes out under the direct-view of digestive endoscopy.
This utility model provides a kind of comparatively ideal artificial esophagus, fistula of operative incision does not take place after the implantation, can induce and promote the growth of the mucosa of newborn esophagus to cover, be highly resistant to the contractility of newborn esophagus scar tissue, prevent the narrow of newborn esophagus, and the mucosa of newborn esophagus cover fully and newborn esophagus scar tissue stable after, can take out or remove by the mode of no wound or Wicresoft's wound.
Description of drawings
Fig. 1 is the structural representation of the tissue engineering combined human body lumen succedaneum of this utility model.
Fig. 2 is the enlarged drawing of cutaway view of the A-A of Fig. 1.
Fig. 3 is the structural representation of single horn mouth tissue engineering combined human body lumen succedaneum of this utility model.
Fig. 4 is the enlarged drawing of cutaway view of the B-B of Fig. 3.
Fig. 5 is the structural representation that the band of this utility model is prevented single horn mouth tissue engineering combined human body lumen succedaneum of recirculation device.
Fig. 6 is the enlarged drawing of cutaway view of the C-C of Fig. 5.
Fig. 7 is the structural representation with the tissue engineering combined human body lumen succedaneum of this utility model of the dismountable type of monofilament braiding.
Fig. 8 is the enlarged drawing of cutaway view of the D-D of Fig. 7.
Fig. 9 is the structural representation of tissue engineering combined human body lumen succedaneum of this utility model of single thread spiral spring type.
Figure 10 is the enlarged drawing of cutaway view of the E-E of Fig. 9.
Figure 11 is the structural representation with the tissue engineering combined human body lumen succedaneum of this utility model of light-wall conduit laser engraving.
Figure 12 is the enlarged drawing of cutaway view of the F-F of Figure 11.
Figure 13 is the structural representation of the tissue engineering combined human body lumen succedaneum of full coat stratotype this utility model.
Figure 14 is the enlarged drawing of cutaway view of the G-G of Figure 13.
Figure 15 is the structural representation of tissue engineering combined human body lumen succedaneum that this utility model of exhausting line has been installed.
Figure 16 is the enlarged drawing of cutaway view of the H-H of Figure 15.
Figure 17 is the fundamental diagram of the tissue engineering combined human body lumen succedaneum of this utility model when implanting.
Figure 18 is the schematic diagram when newborn esophagus was grown after the tissue engineering combined human body lumen succedaneum of this utility model was implanted.
Figure 19 is the pictorial diagram of newborn esophagus specimen.
Figure 20 is the pictorial diagram of newborn esophagus specimen.
Figure 21 is the pictorial diagram of the esophagus mucous layer of newborn esophagus specimen.
Among the above-mentioned figure, 1 is stay pipe, and 2 is connector, but 3 is absorber coatings, and 4 is seed cell, and 5 is exhausting line, and 6 are anti-recirculation device, and 7 is operation suture thread, and 8 is the human body esophagus, and 9 is newborn esophagus, and 10 is the artificial human body intracavity duct of this utility model.
The specific embodiment
Embodiment 1: the tissue engineering combined human body lumen succedaneum of intersection grid type this utility model
Adopting recovery temperature is niti-shaped memorial alloy (Nitinol alloy) silk that 15 ℃ of diameters are 0.25mm, the bracing frame 11 of braiding stay pipe in mould, the heat treatment of in mould, finalizing the design then, make it more than recovery temperature, be cancellated cylinder tube shape, after polishing, the cleaning, promptly obtained bracing frame 11 described in the utility model.
In the medical silica-gel equipment for coating film, stay pipe 11 is installed in the particular manufacturing craft, (, can also have made anti-recirculation device simultaneously to bracing frame 11 overlay films if when making the artificial esophagus of the anti-recirculation device of band according to the common processes of medical silica-gel, with reference to figure 5), pipe 1 is supported.
The terylene ring that adopts braiding is as connector 2, and in the end of stay pipe 1, the distance from the end is 10mm to usefulness operation suture thread 7 with connector 2 sutured.Clean, sterilize, but wait absorber coatings 3 to be sprayed.
The liquid that will include biodegradation material (as gelatin, collagen) and somatomedin (as epidermal growth factor EGF, fibroblast growth factor FGF), inject the ultrasonic atomizatio spray equipment, body 1 is supported in rotation on one side, spraying on one side contains the liquid of somatomedin and biodegradation material, carry out lyophilization simultaneously and handle, but can on the outer wall of stay pipe 1, make absorber coatings 3.But the thickness of absorber coatings 3 is between 1 μ m to 10mm, and preferred values is between 10 μ m to 3000 μ m.
But after carrying out absorber coatings 3, the packing back is with the gamma-ray irradiation sterilization or with the epoxyethane fumigation sterilization, and is stand-by.
Before the clinical operation, with the stay pipe 1 of seed cell 4 suspension inoculations to the above-mentioned preparation of using phosphate (PBS) buffer solution to handle well in advance, obtain the cell-scaffold complex of In vitro culture, promptly obtained the tissue engineering combined human body lumen succedaneum of this utility model, can under aseptic condition, in clinical operation, implant and use.
But above-mentioned absorber coatings 3 is the degradable biomaterial coatings that can use in human body, be selected from: include but not limited to, lactic acid, polyglycolic acid, poly(hydrobutyl ester), poly-anhydride, polycaprolactone, poly-phosphazo, polyphosphazene, polyamino acid, false polyamino acid, poe, polyester urethane, PTMC, Polyethylene Glycol, poly-P-Dioxane ketone, chitosan, collagen, gelatin, hyaluronic acid, chitin, alginate, calcium alginate gel, acellular matrix, bio-vitric, and copolymer or mixture.
But above-mentioned absorber coatings 3 includes somatomedin, is selected from: include but not limited to platelet class somatomedin (platelet source somatomedin, PDGF; Osteosarcoma source somatomedin ODGF), epidermal growth factor subclass (epidermal growth factor, EGF, transforming growth factor, TGF α and TGF β), fibroblast growth factor (FGF, α FGF, β FGF), insulin like growth factor (IGF-I, IGF-II), nerve growth factor (NGF), interleukin class somatomedin (IL-1, IL-2, IL-3 etc.), erythropoietin (EPO), colony stimulating factor (CSF), and composition thereof.
But absorber coatings 3 can also include above-mentioned somatomedin and degradable biomaterial simultaneously.But the thickness of absorber coatings 3 is between 1 μ m to 10mm, and preferred values is between 10 μ m to 3000 μ m.
Seed cell (4) is selected from: from stem cell between stem cell, allogeneic bone marrow between body esophagus mucosal epithelium cell, autologous bone marrow, and composition thereof.
Embodiment 2: the tissue engineering combined human body lumen succedaneum of this utility model that contains the polylactide-ethylene glycol-caprolactone copolymer coating of transforming growth factor
Stay pipe 1 is pressed embodiment 1 preparation.
The terylene ring that adopts braiding is as connector 2, and in the end of stay pipe 1, the distance from the end is 10mm to usefulness operation suture thread 7 with connector 2 sutured.Clean, sterilize, but wait absorber coatings 3 to be sprayed.
With absorbable biological material (as polylactide-ethylene glycol-caprolactone copolymer), with somatomedin (as transforming growth factor TGF α, PDGF etc.) be dissolved in and form suspension in the suitable easy volatile solvent (as acetone), be made into concentration and be 0.01～10% uniform coating solution, standby.
At first the coating solution for preparing is recorded in syringe, adjusting supersonic generator power is that the injection rate of 0.1～5w, syringe floating coat solution is that 0.001～0.1ml/min and compression pressure are 0.2～10psi; Secondly, to support body and be clamped on the particular jig, dividing into the fixed rack speed of moving horizontally at the program software interface and be 0.01～1cm/s, supporting the body rotary speed is that 10～350r/min, direction of rotation, support pipe body movement reciprocal time are that 1～200 time, dry gas pressure are the ventilation velocity 10～1000CFM of 0.2～10psi, exhaust system; Call at last and start spray procedure, supersonic generator produces ultrasound wave, reach on little atomizer by pick off, coating solution under the power of syringe pump by syringe by line transportation to the atomizing face of nozzle, ultrasound wave changes into fine drop with liquid mist, drop flies to the stay pipe surface under the drive of low speed Compressed Gas, form the very thin liquid level of one deck in the stay pipe surface, after treating that organic solvent volatilizees in the liquid level, but the deposition last layer very thin absorber coatings that contains somatomedin in stay pipe surface supports body therebetween and moves back and forth below nozzle;
Support body after the spraying is carried out lyophilization handle, but can on the outer wall of stay pipe 1, make absorber coatings 3.But carry out absorber coatings 3, drying finishes, and packing is back sterilizes with the gamma-ray irradiation sterilization or with epoxyethane fumigation.Before the clinical use, with the stay pipe 1 of seed cell suspension inoculation, in 37 ℃, 5%CO to the above-mentioned preparation of handling well with PBS buffer solution in advance
2Cultivate in the incubator, make seed cell and support further combined with.Careful epithelial cell special culture solution (K-SFM) culture medium that adds behind the 4h is in 37 ℃, 5%CO
2Continue in the incubator to cultivate.After the cultivation of required incubation time, obtain the cell-scaffold complex of In vitro culture, promptly obtained the tissue engineering combined human body lumen succedaneum of this utility model, can under aseptic condition, in clinical operation, implant and use.
Embodiment 3: the tissue engineering combined human body lumen succedaneum of this utility model that contains the polylactide-glycol copolymer coating of bio-vitric
Stay pipe 1 is pressed embodiment 1 preparation.
The terylene ring that adopts braiding is as connector 2, and in the end of stay pipe 1, the distance from the end is 10mm to usefulness operation suture thread 7 with connector 2 sutured.Clean, sterilize, but wait absorber coatings 3 to be sprayed.
With absorbable biological material (as polylactide-glycol copolymer), be dissolved in the suitable easy volatile solvent (as redistilled water+acetone) with bioactivity glass, form suspension or emulsion through ultra-sonic dispersion, be made into concentration and be 0.01～10% uniform coating solution, standby.
Coating solution is injected the ultrasonic atomizatio spray equipment, on one side rotation support body 1, spraying on one side contains the liquid of bioactivity glass and biodegradation material, carries out lyophilization simultaneously and handles, but can make absorber coatings 3 on the outer wall of stay pipe 1.But carry out absorber coatings 3, the packing back is with the gamma-ray irradiation sterilization or with the epoxyethane fumigation sterilization, and is stand-by.
Before the clinical use, with the stay pipe 1 of seed cell suspension inoculation, in 37 ℃, 5%CO to the above-mentioned preparation of handling well with PBS buffer solution in advance
2Cultivate in the incubator, make seed cell and support further combined with.Careful K-SFM culture medium, 37 ℃, the 5%CO of adding behind the 4h
2Continue in the incubator to cultivate.After the cultivation of required incubation time, obtain the cell-scaffold complex of In vitro culture, promptly obtained the tissue engineering combined human body lumen succedaneum of this utility model, can under aseptic condition, in clinical operation, implant and use.
Embodiment 4: the tissue engineering combined human body lumen succedaneum of this utility model that contains the polylactide-glycol copolymer coating of bio-vitric and epidermal growth factor
Stay pipe 1 is pressed embodiment 1 preparation.
The terylene ring that adopts braiding is as connector 2, and in the end of stay pipe 1, the distance from the end is 10mm to usefulness operation suture thread 7 with connector 2 sutured.Clean, sterilize, but wait absorber coatings 3 to be sprayed.
With absorbable biological material (as polylactide-glycol copolymer), be dissolved in the suitable easy volatile solvent (as redistilled water+acetone) with bioactivity glass, form suspension or emulsion through ultra-sonic dispersion, be made into concentration and be 0.01～10% uniform coating solution, standby.Other adopts normal saline preparation epidermal growth factor/polylactide-glycol copolymer solution.
Polylactide-glycol copolymer/bioactivity glass solution and epidermal growth factor/polylactide-glycol copolymer solution are injected the ultrasonic atomizatio spray equipment, adopt the biliquid feed mode, carry out the biliquid spraying.Body 1 is supported in employing rotation on one side, spray the liquid that contains somatomedin and polylactide-glycol copolymer on one side, another nozzle spraying simultaneously contains the solution of bioactivity glass and polylactide-glycol copolymer.Carry out lyophilization simultaneously and handle, but can on the outer wall of stay pipe 1, make absorber coatings 3.But carry out absorber coatings 3, the packing back is with the gamma-ray irradiation sterilization or with the epoxyethane fumigation sterilization, and is stand-by.
Before the clinical use, with the stay pipe 1 of seed cell suspension inoculation, in 37 ℃, 5%CO to the above-mentioned preparation of handling well with PBS buffer solution in advance
2Cultivate in the incubator, make cell and support further combined with.The careful K-SFM culture medium that adds behind the 4h is in 37 ℃, 5%CO
2Continue in the incubator to cultivate.After the cultivation of required incubation time, obtain the seed cell-scaffold complex of In vitro culture, promptly obtained the tissue engineering combined human body lumen succedaneum of this utility model, can under aseptic condition, in clinical operation, implant and use.
Embodiment 5: the tissue engineering combined human body lumen succedaneum of this utility model that contains the polylactide-glycol copolymer/acellular matrix composite coating of epidermal growth factor
Stay pipe 1 is pressed embodiment 1 preparation.
The terylene ring that adopts braiding is as connector 2, and in the end of stay pipe 1, the distance from the end is 10mm to usefulness operation suture thread 7 with connector 2 sutured.Clean, sterilize, but wait absorber coatings 3 to be sprayed.
With absorbable biological material (as polylactide-glycol copolymer), be dissolved in the suitable easy volatile solvent (as redistilled water+acetone) with acellular matrix, form suspension or emulsion through ultra-sonic dispersion, be made into concentration and be 0.01～10% uniform coating solution, standby.Other adopts normal saline preparation epidermal growth factor/polylactide-glycol copolymer solution.
Polylactide-glycol copolymer/acellular matrix solution and epidermal growth factor/polylactide-glycol copolymer solution are injected the ultrasonic atomizatio spray equipment, adopt the biliquid feed mode, carry out the biliquid spraying.Adopt rotation on one side to support body 1, Yi Bian spray polylactide-glycol copolymer), with acellular matrix solution, another nozzle spraying epidermal growth factor/polylactide-glycol copolymer solution of while.Carry out lyophilization simultaneously and handle, but can on the outer wall of stay pipe 1, make absorber coatings 3.But carry out absorber coatings 3, the packing back is with the gamma-ray irradiation sterilization or with the epoxyethane fumigation sterilization, and is stand-by.
Before the clinical use with the stay pipe 1 of seed cell suspension inoculation, in 37 ℃, 5%CO to the above-mentioned preparation of handling well with PBS buffer solution in advance
2Cultivate in the incubator, make seed cell and support further combined with.Careful K-SFM culture medium, 37 ℃, the 5%CO of adding behind the 4h
2Continue in the incubator to cultivate.After the cultivation of required incubation time, obtain the cell-scaffold complex of In vitro culture, promptly obtained the tissue engineering combined human body lumen succedaneum of this utility model, can under aseptic condition, in clinical operation, implant and use.
Embodiment 6: the tissue engineering combined human body lumen succedaneum of this utility model that contains the collagen/acellular matrix composite coating of transforming growth factor and epidermal growth factor
Stay pipe 1 is pressed embodiment 1 preparation.
The terylene ring that adopts braiding is as connector 2, and in the end of stay pipe 1, the distance from the end is 10mm to usefulness operation suture thread 7 with connector 2 sutured.Clean, sterilize, but wait absorber coatings 3 to be sprayed.
With absorbable biological material (as collagen or gelatin), be dissolved in the suitable easy volatile solvent (as normal saline+acetone) with epidermal growth factor, form suspension or emulsion through ultra-sonic dispersion, be made into concentration and be 0.01～10% uniform coating solution, standby.Other adopts normal saline preparation transforming growth factor/acellular matrix copolymer solution.
Transforming growth factor/acellular matrix solution and epidermal growth factor/collagen solution are injected the ultrasonic atomizatio spray equipment, adopt the biliquid feed mode, carry out the biliquid spraying.Adopt rotation on one side to support body 1, Yi Bian spray transforming growth factor/acellular matrix solution, another nozzle spraying epidermal growth factor/collagen solution of while.Carry out lyophilization simultaneously and handle, but can on the outer wall of stay pipe 1, make absorber coatings 3.But carry out absorber coatings 3, the packing back is with the gamma-ray irradiation sterilization or with the epoxyethane fumigation sterilization, and is stand-by.Before the clinical use with the stay pipe 1 of seed cell suspension inoculation to the above-mentioned preparation of handling well with PBS buffer solution in advance, promptly obtained the tissue engineering combined human body lumen succedaneum of this utility model, can under aseptic condition, in clinical operation, implant and use.
Embodiment 7: the tissue engineering combined human body lumen succedaneum of this utility model that contains the polylactide-glycol copolymer/chitosan composite coating of fibroblast growth factor (FGF) and epidermal growth factor
Stay pipe 1 is pressed embodiment 1 preparation.
The terylene ring that adopts braiding is as connector 2, and in the end of stay pipe 1, the distance from the end is 10mm to usefulness operation suture thread 7 with connector 2 sutured.Clean, sterilize, but wait absorber coatings 3 to be sprayed.
With absorbable biological material (as polylactide-glycol copolymer), be dissolved in the suitable easy volatile solvent (as normal saline+acetone) with epidermal growth factor, form suspension or emulsion through ultra-sonic dispersion, be made into concentration and be 0.01～10% uniform coating solution, standby.Other adopts normal saline to be mixed with fibroblast growth factor (FGF)/chitosan solution.
Epidermal growth factor/polylactide-glycol copolymer solution and fibroblast growth factor (FGF)/chitosan solution are injected the ultrasonic atomizatio spray equipment, adopt the biliquid feed mode, carry out the biliquid spraying.Adopt rotation on one side to support body 1, Yi Bian spray epidermal growth factor/polylactide-glycol copolymer solution, another nozzle spraying fibroblast growth factor (FGF)/chitosan solution of while.Carry out lyophilization simultaneously and handle, but can on the outer wall of stay pipe 1, make absorber coatings 3.But carry out absorber coatings 3, the packing back is with the gamma-ray irradiation sterilization or with the epoxyethane fumigation sterilization, and is stand-by.Before the clinical use with the stay pipe 1 of seed cell suspension inoculation, in 37 ℃, 5%CO to the above-mentioned preparation of handling well with PBS buffer solution in advance
2Cultivate in the incubator, make seed cell and support further combined with.Careful K-SFM culture medium, 37 ℃, the 5%CO of adding behind the 4h
2Continue in the incubator to cultivate.After the cultivation of required incubation time, obtain the cell-scaffold complex of In vitro culture, promptly obtained the tissue engineering combined human body lumen succedaneum of this utility model, can under aseptic condition, in clinical operation, implant and use.
Embodiment 8: the tissue engineering combined human body lumen succedaneum of this utility model that contains the bio-vitric/collagen composite coating of fibroblast growth factor (FGF) and epidermal growth factor
Stay pipe 1 is pressed embodiment 1 preparation.
The terylene ring that adopts braiding is as connector 2, and in the end of stay pipe 1, the distance from the end is 10mm to usefulness operation suture thread 7 with connector 2 sutured.Clean, sterilize, but wait absorber coatings 3 to be sprayed.
With absorbable biological material (as collagen), be dissolved in the suitable easy volatile solvent (as normal saline+acetone) with epidermal growth factor, form suspension or emulsion through ultra-sonic dispersion, be made into concentration and be 0.01～10% uniform coating solution, standby.Other adopts normal saline to be mixed with fibroblast growth factor (FGF)/bio-vitric solution.
Epidermal growth factor/collagen solution and fibroblast growth factor (FGF)/bio-vitric solution are injected the ultrasonic atomizatio spray equipment, adopt the biliquid feed mode, carry out the biliquid spraying.Adopt rotation on one side to support body 1, Yi Bian spray epidermal growth factor/collagen solution, another nozzle spraying fibroblast growth factor (FGF)/bio-vitric solution of while.Carry out lyophilization simultaneously and handle, but can on the outer wall of stay pipe 1, make absorber coatings 3.But carry out absorber coatings 3, the packing back is with the gamma-ray irradiation sterilization or with the epoxyethane fumigation sterilization, and is stand-by.Before the clinical use with the stay pipe 1 of seed cell suspension inoculation to the above-mentioned preparation of handling well with PBS buffer solution in advance, obtain the cell-scaffold complex of In vitro culture, promptly obtained the tissue engineering combined human body lumen succedaneum of this utility model, can under aseptic condition, in clinical operation, implant and use.
Embodiment 9: the tissue engineering combined human body lumen succedaneum of this utility model that contains the chitosan coat of bio-vitric and epidermal growth factor
Stay pipe 1 is pressed embodiment 1 preparation.
The terylene ring that adopts braiding is as connector 2, and in the end of stay pipe 1, the distance from the end is 10mm to usefulness operation suture thread 7 with connector 2 sutured.Clean, sterilize, but wait absorber coatings 3 to be sprayed.
With absorbable biological material (as chitosan), be dissolved in the suitable easy volatile solvent (as redistilled water+acetone) with bioactivity glass, form suspension or emulsion through ultra-sonic dispersion, be made into concentration and be 0.01～10% uniform coating solution, standby.Other adopts normal saline preparation epidermal growth factor/chitin copolymer solution.
Chitosan/bioactivity glass solution and epidermal growth factor/chitosan solution are injected the ultrasonic atomizatio spray equipment, adopt the biliquid feed mode, carry out the biliquid spraying.Adopt rotation on one side to support body 1, on one side spraying contain epidermal growth factor/chitosan solution, another nozzle spraying chitosan-containing/bioactivity glass solution simultaneously.Carry out lyophilization simultaneously and handle, but can on the outer wall of stay pipe 1, make absorber coatings 3.But carry out absorber coatings 3, the packing back is with the gamma-ray irradiation sterilization or with the epoxyethane fumigation sterilization, and is stand-by.Before the clinical use with the stay pipe 1 of seed cell suspension inoculation to the above-mentioned preparation of handling well with PBS buffer solution in advance, obtain the cell-scaffold complex of In vitro culture, promptly obtain the tissue engineering combined human body lumen succedaneum of this utility model, can in clinical operation, implant use.
Should be noted that herein openly can replace with the identical structure of other effect that the embodiment that while this utility model is introduced realizes unique structure of the present utility model with the structure of explanation.Though preferential enforcement of the present utility model is introduced in this article and is illustrated; but those skilled in the art know clearly that these embodiment illustrate; those skilled in the art can make countless variations, improvement and replacement; and can not break away from this utility model; therefore, should limit protection domain of the present utility model according to the spirit and scope of this utility model appending claims.
Claims (33)
1, tissue engineering combined human body lumen succedaneum is characterized in that: by stay pipe (1), connector (2) but absorber coatings (3) and seed cell (4) are formed; Described stay pipe (1) is made of flexible supporting frames (11) and flexible material film (12), and flexible material film (12) is attached on the flexible supporting frames (11); But on the outer wall of absorber coatings (3) attached to stay pipe (1); Seed cell (4) but be planted on the absorber coatings (3); Connector (2) is fixed on the position of close end of stay pipe (1).
2, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: described flexible supporting frames (11) is the network structure body that medical metal material silk or fibrage become; Or the network structure body of the helical spring of medical metal material spun gold coiled composition; Or the crooked resilient medical metal material thin-walled network structure body of energy through forming after the digital control processing; Or through the crooked resilient medical metal material thin-walled network structure body of energy behind the laser engraving.
3, according to the described tissue engineering combined human body lumen succedaneum of claim 2, it is characterized in that: described medical metal material is selected from: niti-shaped memorial alloy, beta-titanium alloy, medical stainless steel, medical zircaloy, medical zirconium-niobium alloy.
4, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: described connector (2) is the circulus with the medical flexible material manufacture.
5, according to the described tissue engineering combined human body lumen succedaneum of claim 4, it is characterized in that: described connector (2) is with medical flexible material silk or fiber, by the circulus of braiding or knitting manufacturing, the medical flexible material that connector (2) adopts is selected from: terylene, polyethylene, polypropylene, polyurethane, politef.
6, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: but described absorber coatings (3) is the absorbable biological material coating that can use in human body, is selected from: polylactic acid, polyglycolic acid, poly(hydrobutyl ester), poly-anhydride, polycaprolactone, poly-phosphazo, polyphosphazene, polyamino acid, false polyamino acid, poe, the polyester urethane, PTMC, Polyethylene Glycol, poly-P-Dioxane ketone, chitosan, collagen, gelatin, hyaluronic acid, chitin, alginate, calcium alginate gel, acellular matrix, bio-vitric.
7, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: but described absorber coatings (3) includes somatomedin, is selected from: platelet class somatomedin, epidermal growth factor subclass, fibroblast growth factor, insulin like growth factor, nerve growth factor, interleukin class somatomedin, erythropoietin, colony stimulating factor.
8, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: described seed cell (4) is selected from: from stem cell between stem cell, allogeneic bone marrow between body esophagus mucosal epithelium cell, autologous bone marrow.
9, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: but described absorber coatings (3) includes somatomedin and collagen.
10, according to the described tissue engineering combined human body lumen succedaneum of claim 9, it is characterized in that: but described absorber coatings (3) includes fibroblast growth factor and collagen.
11, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: but described absorber coatings (3) includes somatomedin, collagen and chitosan.
12, according to the described tissue engineering combined human body lumen succedaneum of claim 11, it is characterized in that: but described absorber coatings (3) includes fibroblast growth factor, collagen and chitosan.
13, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: but described absorber coatings (3) includes somatomedin and acellular matrix.
14, according to the described tissue engineering combined human body lumen succedaneum of claim 13, it is characterized in that: but described absorber coatings (3) includes fibroblast growth factor and acellular matrix.
15, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: but described absorber coatings (3) includes somatomedin, collagen and acellular matrix.
16, according to the described tissue engineering combined human body lumen succedaneum of claim 15, it is characterized in that: but described absorber coatings (3) includes fibroblast growth factor, collagen and acellular matrix.
17, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: but described absorber coatings (3) includes somatomedin and polylactic acid.
18, according to the described tissue engineering combined human body lumen succedaneum of claim 17, it is characterized in that: but described absorber coatings (3) includes fibroblast growth factor and polylactic acid.
19, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: but described absorber coatings (3) includes somatomedin and polylactic acid-polycaprolactone copolymer.
20, according to the described tissue engineering combined human body lumen succedaneum of claim 19, it is characterized in that: but described absorber coatings (3) includes fibroblast growth factor and polylactic acid-polycaprolactone copolymer.
21, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: but described absorber coatings (3) includes somatomedin and bio-vitric.
22, according to the described tissue engineering combined human body lumen succedaneum of claim 21, it is characterized in that: but described absorber coatings (3) includes fibroblast growth factor and bio-vitric.
23, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: but described absorber coatings (3) includes somatomedin, collagen and bio-vitric.
24, according to the described tissue engineering combined human body lumen succedaneum of claim 23, it is characterized in that: but described absorber coatings (3) includes fibroblast growth factor, collagen and bio-vitric.
25, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: described stay pipe (1) can have different geometries, has: cylinder tube shape, the single bell-mouthed cylinder tube shape of band, the two single bell-mouthed cylinder tube shapes of band.
26, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: described flexible material film (12) is to be selected from: medical silica-gel, polyurethane, politef at the thin film of the medium-term and long-term medical flexible material manufacture of implanting of human body.
27, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: described connector (2) passes through operation suture thread (7) sutured on stay pipe (1).
28, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: the exhausting line (5) that takes out body has been installed in the upper end of described stay pipe (1).
29, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: the lower end of described stay pipe (1) is provided with anti-recirculation device (6).
30, according to the described tissue engineering combined human body lumen succedaneum of claim 29, it is characterized in that: described anti-recirculation device (6) is petal-shaped structure, has: 2 lobe formula structures, 3 lobe formula structures, 4 lobe formula structures, 5 lobe formula structures, 6 lobe formula structures.
31, according to the described tissue engineering combined human body lumen succedaneum of claim 29, it is characterized in that: described anti-recirculation device (6) is an oversleeve type check valve-type structure.
32, according to the described tissue engineering combined human body lumen succedaneum of claim 1, it is characterized in that: but the thickness of described absorber coatings (3) is between 1 μ m to 10mm.
33, according to the described tissue engineering combined human body lumen succedaneum of claim 32, it is characterized in that: but the thickness of described absorber coatings (3) is between 10 μ m to 3000 μ m.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2008202018743U CN201316330Y (en) | 2008-10-15 | 2008-10-15 | Combined tissue-engineered coelomic duct substitute |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2008202018743U CN201316330Y (en) | 2008-10-15 | 2008-10-15 | Combined tissue-engineered coelomic duct substitute |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201316330Y true CN201316330Y (en) | 2009-09-30 |
Family
ID=41195103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2008202018743U Expired - Fee Related CN201316330Y (en) | 2008-10-15 | 2008-10-15 | Combined tissue-engineered coelomic duct substitute |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201316330Y (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010043177A1 (en) * | 2008-10-15 | 2010-04-22 | Zhou Xing | Human body tube substitute of biological induction type |
| CN102038564A (en) * | 2009-10-14 | 2011-05-04 | 周星 | Supporting frame capable of being taken out |
| CN108939158A (en) * | 2018-07-27 | 2018-12-07 | 吉林大学 | Small intestine acellular matrix film combination metal mesh breast wall repairing material |
| WO2021233359A1 (en) * | 2020-05-20 | 2021-11-25 | 中国医学科学院肿瘤医院 | Transplant stent and transplant stent delivery system |
-
2008
- 2008-10-15 CN CNU2008202018743U patent/CN201316330Y/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010043177A1 (en) * | 2008-10-15 | 2010-04-22 | Zhou Xing | Human body tube substitute of biological induction type |
| CN102038564A (en) * | 2009-10-14 | 2011-05-04 | 周星 | Supporting frame capable of being taken out |
| CN108939158A (en) * | 2018-07-27 | 2018-12-07 | 吉林大学 | Small intestine acellular matrix film combination metal mesh breast wall repairing material |
| WO2021233359A1 (en) * | 2020-05-20 | 2021-11-25 | 中国医学科学院肿瘤医院 | Transplant stent and transplant stent delivery system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038564A (en) | Supporting frame capable of being taken out | |
| Orabi et al. | Tissue engineering of urinary bladder and urethra: advances from bench to patients | |
| US8968401B2 (en) | Synthetic scaffolds and organ and tissue transplantation | |
| US8663675B2 (en) | Injectable matrix having a polymer and a stem cell niche composed of cup-shaped nanoparticles containing growth factors or physiological agents for organ reconstruction | |
| ES2703785T3 (en) | Method and composition to treat an inflammatory bowel disease without colectomy | |
| CN1529653A (en) | Biodegradable and/or biological absorbing fiber product and its use in medical application | |
| CN101856517B (en) | Tissue engineering material-based culture method and applications of melanophore | |
| KR20100046037A (en) | Prosthesis for promoting the in vivo reconstruction of a hollow organ or a portion of a hollow organ | |
| CN201316331Y (en) | Biologically induced composite artificial esophagus | |
| CN101721262A (en) | Tissue engineering combined human body lumen succedaneum | |
| CN201316330Y (en) | Combined tissue-engineered coelomic duct substitute | |
| JP2019529015A (en) | Dermal layer for transplantation with increased survival rate and method for producing the same | |
| CN201572218U (en) | Supporting rack capable of being taken out | |
| Walles | Bioartificial tracheal grafts: can tissue engineering keep its promise? | |
| CN101721263A (en) | Biologically induced composite artificial esophagus | |
| WO2010043177A1 (en) | Human body tube substitute of biological induction type | |
| Klin et al. | Experimental repair of tracheal defects using a new biodegradable membrane | |
| CN114177355B (en) | Composite artificial bile duct and preparation method thereof | |
| CN219462040U (en) | Artificial esophagus | |
| CN108440645A (en) | A kind of biologically active polypeptide and its application | |
| Kirpatovskii et al. | Collagen-1 membrane for replacing the bladder wall | |
| CN209137484U (en) | Tissue repair sticking patch and main body | |
| RU2369358C1 (en) | Arrangement of construction of transplanted live dermal skin equivalent for treatment of bronchopleurothoracal fistulas in case of fibrous-cavernous lung tuberculosis | |
| Grower et al. | Segmental neogenesis of the dog esophagus utilizing a biodegradable polymer framework | |
| Harmon et al. | Translational Research Into New Clinical Applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090930 Termination date: 20151015 |
|
| EXPY | Termination of patent right or utility model |